{"organizations": [], "uuid": "e233d6fc72628b3a91efcec7d65741a904f98f66", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-akebia-therapeutics-announces-posi/brief-akebia-therapeutics-announces-positive-results-from-study-of-vadadustat-in-japanese-idUSFWN1OZ0B2", "country": "US", "domain_rank": 408, "title": "BRIEF-Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:33:00.000+02:00", "replies_count": 0, "uuid": "e233d6fc72628b3a91efcec7d65741a904f98f66"}, "author": "", "url": "https://www.reuters.com/article/brief-akebia-therapeutics-announces-posi/brief-akebia-therapeutics-announces-positive-results-from-study-of-vadadustat-in-japanese-idUSFWN1OZ0B2", "ord_in_thread": 0, "title": "BRIEF-Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "vadadustat in japanese reuters", "sentiment": "none"}, {"name": "akebia therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 12:34 PM / Updated 9 minutes ago BRIEF-Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese Reuters Staff 1 Min Read \nJan 4 (Reuters) - Akebia Therapeutics Inc: \n* AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA ASSOCIATED WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE * DATA CONSISTENT WITH FINDINGS FROM PREVIOUS STUDIES​ \n* ‍PHASE 3 STUDY OF NON-DIALYSIS PATIENTS IN JAPAN ONGOING; PHASE 3 STUDIES OF DIALYSIS PATIENTS TO BEGIN IN 2018​ \n* STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT OBSERVED IN VADADUSTAT GROUP 150 MG (P = 0.0004) COMPARED TO PLACEBO​ \n* STATISTICALLY SIGNIFICANT IMPROVEMENTS ALSO OBSERVED IN VADADUSTAT GROUPS 300 MG(P<0.0001), 600 MG(P< 0.0001),COMPARED TO PLACEBO​ \n* SERIOUS ADVERSE EVENTS WERE CONSISTENT WITH PRIOR STUDIES \n* NO DEATHS WERE REPORTED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T14:33:00.000+02:00", "crawled": "2018-01-04T14:47:21.028+02:00", "highlightTitle": ""}